CEPHEID (CPHD, Financial) filed Annual Report for the period ended 2010-12-31.
Cepheid has a market cap of $1.49 billion; its shares were traded at around $24.715 with and P/S ratio of 7. Hedge Fund Gurus that owns CPHD: Manning & Napier Advisors, Inc, Bruce Kovner of Caxton Associates, Steven Cohen of SAC Capital Advisors. Mutual Fund and Other Gurus that owns CPHD: Columbia Wanger of Columbia Wanger Asset Management, PRIMECAP Management, Mario Gabelli of GAMCO Investors.
The principal objective of our research and development program is to develop high-value clinical diagnostic products for the GeneXpert system. We focus our efforts on four main areas: a) assay development efforts to design, optimize, and produce specific tests that leverage the systems and chemistry we have developed, b) target discovery research to identify novel micro RNA targets to be used in the development of future assays, c) chemistry research to develop innovative and proprietary methods to design and synthesize oligonucleotide primers, probes and dyes to optimize the speed, performance and ease-of-use of our assays and d) engineering efforts to extend the multiplexing capabilities of our systems and to develop new low and high throughput systems. Total research and development expense was $42.5 million, $39.3 million and $43.3 million for the years ended December 31, 2010, 2009 and 2008, respectively.
Novartis. In October 2010, we entered into a collaboration with Novartis for the commercialization of a test for monitoring the BCR-ABL gene transcript in peripheral blood specimens from patients diagnosed with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). To fund development and clinical trial costs, we received an upfront fee of $5.0 million in October 2010 from Novartis with up to $3.0 million in milestone payments over the ensuing 12 months. If the FDA grants us clearance to commercially release the product in the U.S., under the collaboration, Novartis will have exclusive global distribution rights to the Xpert BCR-ABL test under a Cepheid/Novartis label.
Read the The complete Report
Cepheid has a market cap of $1.49 billion; its shares were traded at around $24.715 with and P/S ratio of 7. Hedge Fund Gurus that owns CPHD: Manning & Napier Advisors, Inc, Bruce Kovner of Caxton Associates, Steven Cohen of SAC Capital Advisors. Mutual Fund and Other Gurus that owns CPHD: Columbia Wanger of Columbia Wanger Asset Management, PRIMECAP Management, Mario Gabelli of GAMCO Investors.
Highlight of Business Operations:
As of June 30, 2010, the last business day of the Registrants most recently completed second fiscal quarter, the aggregate market value of the common stock held by non-affiliates of the registrant was approximately $931,354,772 based on the closing sale price for the registrants common stock on the NASDAQ Global Select Market on that date of $16.02 per share. This number is provided only for the purpose of this report on Form 10-K and does not represent an admission by either the registrant or any such person as to the status of such person.The principal objective of our research and development program is to develop high-value clinical diagnostic products for the GeneXpert system. We focus our efforts on four main areas: a) assay development efforts to design, optimize, and produce specific tests that leverage the systems and chemistry we have developed, b) target discovery research to identify novel micro RNA targets to be used in the development of future assays, c) chemistry research to develop innovative and proprietary methods to design and synthesize oligonucleotide primers, probes and dyes to optimize the speed, performance and ease-of-use of our assays and d) engineering efforts to extend the multiplexing capabilities of our systems and to develop new low and high throughput systems. Total research and development expense was $42.5 million, $39.3 million and $43.3 million for the years ended December 31, 2010, 2009 and 2008, respectively.
Novartis. In October 2010, we entered into a collaboration with Novartis for the commercialization of a test for monitoring the BCR-ABL gene transcript in peripheral blood specimens from patients diagnosed with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). To fund development and clinical trial costs, we received an upfront fee of $5.0 million in October 2010 from Novartis with up to $3.0 million in milestone payments over the ensuing 12 months. If the FDA grants us clearance to commercially release the product in the U.S., under the collaboration, Novartis will have exclusive global distribution rights to the Xpert BCR-ABL test under a Cepheid/Novartis label.
Read the The complete Report
